InflaRx N.V. (NASDAQ:IFRX) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of InflaRx N.V. (NASDAQ:IFRX) have received a consensus rating of “Moderate Buy” from the seven research firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $7.00.

Several brokerages have recently weighed in on IFRX. Wall Street Zen raised InflaRx from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Guggenheim reaffirmed a “buy” rating and issued a $14.00 price objective on shares of InflaRx in a research note on Tuesday, April 21st. HC Wainwright increased their target price on shares of InflaRx from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Weiss Ratings restated a “sell (d-)” rating on shares of InflaRx in a report on Friday, March 27th. Finally, Cantor Fitzgerald boosted their price target on shares of InflaRx from $2.00 to $4.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th.

InflaRx Stock Performance

Shares of NASDAQ:IFRX opened at $1.66 on Wednesday. The firm has a market cap of $120.00 million, a PE ratio of -2.34 and a beta of 2.42. The firm’s fifty day moving average is $1.83 and its 200-day moving average is $1.29. InflaRx has a 52 week low of $0.74 and a 52 week high of $2.95.

InflaRx (NASDAQ:IFRX) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.08. Sell-side analysts forecast that InflaRx will post -0.4 EPS for the current year.

Hedge Funds Weigh In On InflaRx

Several hedge funds and other institutional investors have recently bought and sold shares of IFRX. Cubist Systematic Strategies LLC grew its holdings in InflaRx by 33.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock worth $31,000 after acquiring an additional 7,616 shares during the period. HRT Financial LP acquired a new stake in InflaRx during the fourth quarter worth approximately $47,000. Concurrent Investment Advisors LLC grew its stake in InflaRx by 56.9% during the fourth quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company’s stock worth $53,000 after purchasing an additional 19,200 shares during the period. Insigneo Advisory Services LLC bought a new stake in InflaRx in the fourth quarter worth approximately $61,000. Finally, Quadrature Capital Ltd acquired a new position in InflaRx in the fourth quarter valued at approximately $104,000. Institutional investors and hedge funds own 42.39% of the company’s stock.

About InflaRx

InflaRx N.V. is a clinical?stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement?1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX?1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro?inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high?unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.